Lilly Boosts 2026 Sales Guidance Amid Strong Demand for Obesity Drugs
Guidance·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Eli Lilly & Co. boosted its 2026 sales guidance after its weight-loss drug franchise performed far better than expected in the second quarter, helping to counter investor concerns that the obesity drug boom is starting to slow.
A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly's performance continues to thrive in the competitive obesity drug market.
Eli LillyNovo
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Eli Lilly & Co. boosted its 2026 sales guidance after its weight-loss drug franchise performed far better than expected in the second quarter, helping to counter investor concerns that the obesity drug boom is starting to slow.”
Bloomberg — Lilly Jumps as Obesity Drug Boom Shows No Sign of Slowing“A research disappointment and a miss on Wegovy pill sales hurt Novo, while”
biopharma dive — Lilly climbs, Novo falls as obesity drug battle intensifies